NCT06252298View on ClinicalTrials.gov

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

August 28, 2025

Study Completion Date

February 28, 2027

Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
BIOLOGICAL

SCTC21C

SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease

Trial Locations (1)

Unknown

RECRUITING

Beijing Chaoyang Hospital ,Capital Medical University, Beijing

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY